Curriculum Vitae
Armando A. Genazzani

Born on September 22, 1968 in New York (USA)
Nationality: Dual National (Italian, American)
Mobile phone:
e-mail: armando.genazzani@unito.it

Work address: Università degli Studi di Torino
Department of Drug Science and Technology
Via Pietro Giuria, 13, 10125 Torino, Italy

Education and qualifications

2024 – present	**Full Professor of Pharmacology,** Università degli Studi di Torino, Italy
2019 – 2023	**Head of Department** – Department of Pharmaceutical Sciences, Università del Piemonte Orientale, Italy
2011 - 2023	**Full Professor of Pharmacology,** Università del Piemonte Orientale, Italy
2008	**Premio Galeno** for young talented Italian scientists in the pharmacological field.
2003 – 2011	**Associate Professor,** Università del Piemonte Orientale, Italy
2000 – 2003	**University Lecturer,** Department of Pharmacology, University of Cambridge, UK
2000 – 2003	**Clare Hall Fellow and Graduate Tutor,** University of Cambridge, UK
1998 – 2000	**Cambridge Pharmacology Fellow and BBSRC David Phillips Fellow,** Department of Pharmacology, University of Cambridge, UK
1997	**Peter Baker Fellowship** at the Marine Biology Association of the UK (Plymouth)
1997 – 1998	**EMBO long-term Fellow,** Department of Biochemistry, ETH, Zurich
1995 – 1997	**Post-doctoral Fellow and *D.Phil.* student,** Department of Pharmacology, University of Oxford, UK
1993	**Board Registration for Medical Practice**
1987- 1993	**Degree in Medicine and Surgery,** Università di Catania, Italy

Scientific interests

I have published over **230** papers, with a googlescholar h-index of **68** and around **200** of these have been cited at least 10 times (https://scholar.google.com/citations?user=nzrp_cgAAAAJ&hl=en&oi=ao) and am a named inventor on 5 patents. The 10 most representative publications relevant to this application are at the end of this CV.

My main current research interests are:

- Role of NAMPT and NAPRT, two key enzymes in the biosynthesis of NAD which also act as secreted cytokines, in cancer and inflammation and development of drugs acting on these proteins (inhibitors, neutralizing antibodies);
- Development of a therapy for tubular aggregate myopathy, an ultra-rare disease triggered by gain-of-function mutations of proteins involved in store-operated Ca^{2+}-entry;
- Role of calcineurin in astrocytes as a transcriptional switch in health and disease, with particular emphasis in neurodegenerative disorders;
- Mitochondrial-ER interactions, with particular emphasis on Ca^{2+}-shuttling;
- Development of tools to target transcription factors in oncology.

Health Policy and Regulatory Affairs

2024 – present	Member of an **Ethical Review Board,** Città della Salute e della Scienza di Torino
2023 – 2025	**Tumour Molecular Board** Member of the Piedmont Region.
2022 – 2023	Pharmacologist in the Phase I clinical trial Unit, **Ospedale Maggiore della Carità (Novara).**
2021 – present	**Scientific Director of the pharmacovigilance center and of the drug documentation center of the Piedmont Region.** The Director coordinates scientific activities relating to passive and active pharmacovigilance activities in the Region (4 million inhabitants).

2020 – 2023	**Representative of Italy in the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA).** The CHMP issues final recommendations to the European Commission on the benefit/risk of new drugs and indications.
2018 – 2019	**Member of the "Expert Committee on the Selection and Use of Essential Medicines" of the World Health Organization.** This Committee chooses drugs that should be available globally based on the extent of benefit/risk and revises the list biannually.
2016 – 2018	Member of ***ad hoc* committees on biosimilars and on Ebola drug readiness.** These are *ad hoc* committees summoned to tackle urgent global health problems.
2015 – 2024	**Member of the Technical and Scientific Committee of the Italian Medicines agency (CTS AIFA).** This is the main external Committee of the Agency and decides on access of drugs to the Italian market, reimbursement from the NHS and patient populations to treat.
2014 – 2018	**Member of** the "Expert Advisory Panel on the international pharmacopoeia and pharmaceutical preparations" serving the **"International Non-Proprietary Names Committee for Pharmaceutical Substances" of the World Health Organization.** This Committee issues names to new active principles based on a number of elements, including mechanism of action and similarity to other drugs.
2013 – 2020	Member of **Ethical Review Boards** (Novara, Sardinia Region, Valle D'Aosta Region)– Ethical Review Boards evaluate clinical trial proposal based on scientific soundness and ethical principles.

Learned Societies and Participation in National Pharmacological Activities

2024 – 2026	**President of the Italian Society of Pharmacology;** the Society has roughly 1600 members and aggregates university and non-university members.
2020 – 2021	**Committee** evaluating the mandatory suitability **("habilitation ")** of candidates to participate in post advertisements in pharmacology.
2019 – present	**Senior coordinator** of the "under 35 pharmacology group" of the Italian Society of Pharmacology.
2018 – present	Member of **grant panels.** In particular, I am in the grant panel of the Italian Medicines Agency for clinical research and in the grant panel of the Fondazione Cariparo for research conducted in the Northeast of Italy.
2003 – present	Member of appointment Committees for assistant, associate and full Professors in a number of Italian Universities.
2000 – present	Reviewer of grants for British, Italian, French, Belgian, European, Hong Kong institutions.
1999 – present	Member of Ph.D. Committees in a number of British and Italian institutions.
2013 – 2015	Member of the Board of the Italian Society of Pharmacology.

Undergraduate Teaching

2024 – present Università degli Studi di Torino – Pharmacy, Medicine, Biotechnology.

2003 – 2023 Università del Piemonte Orientale – Pharmacy, Medicine, Biotechnology (general principles of pharmacology, pharmacotherapy, bioethics of clinical trials, toxicology).

1998 – 2003 University of Cambridge – Natural Science Tripos, Medical and Veterinary Science Tripos, Part II Pharmacology, Neuroscience (neuropsychopharmacology, signal transduction).

Graduate Teaching, Supervision, and Coordination

2019 – 2023 Organization and Coordination of Erasmus Mundus Joint Master Degree "The European Master on Translational Cosmetic and Dermatological Sciences" (www.emotion-master.eu). This Master is funded on a competitive basis by the EU with 2.6 million euros. It involves 4 European Universities and enrolls students from all the world with scholarships. Last year, the Master received over 500 applications worldwide for 30 places.

2007 – 2023 Organization and Coordination of a Master Course in "Regulatory Affairs and Market access" (www.drmka-master.it). This Master, in Italian, is designed to develop those skills

required to work in the pharmaceutical industry sector. It has an average intake of 20 students per year, most of which secure internships in industry. It is one of the most successful Masters of this kind in Italy and has made net gains for the university (*i.e.* expenditure versus students fees) since its first edition.

Public understanding of science

2018 – present **Book reviews** I routinely write articles for the oldest- standing book review journal in Italy (L'indice dei Libri; https://www.lindiceonline.com/).

2014 – present **Public events** I have routinely given lectures to school-age children (from primary to high school) and to patients relating drugs. In the last year, I have also been interviewed several times on national newspapers, radios and TV regarding vaccines and drugs for COVID-19. I have also been invited to speak twice (2016 and 2021) to Trieste Next, one of the largest National Science Festivals in Italy.

Research Funding

Current funding on a competitive basis: Ministry of Universities and Research, Telethon Foundation.

Other current funding: Piedmont Region for pharmacovigilance activities.

2003 – 2021 **Università del Piemonte Orientale** – Research grants from the Ministry of Universities and Research, the Ministry of Health, the Piedmont Region, the European Union, the Cariplo Foundation, the Compagnia San Paolo Foundation, and the Italian Association of Cancer Research.

1998 – 2003 **University of Cambridge** – Research grants from the BBSRC, The Royal Society, Action Research UK, Human Frontiers Science Program, British Heart Foundation.

Editorial activity

2023 – present	**Co-Editor** of the Italian textbook "Farmacologia: principi di base e applicazioni terapeutiche"
2023 – present	**Co-Editor** of the Italian textbook "Farmacologia"
2018 – present	**Editorial Board Member**, Frontiers in Pharmacology
2007 – present	**Editorial Board Member**, Pharmacological Research

University Governance

2024 – present	**Vice Head of Department** with mandate on teaching activities, Department of
2019 – 2023	Drug Science and Technology, Università di Torino **Member of University Senate,** Università del Piemonte Orientale
2016 – 2018	**Delegate of the Chancellor for international Affairs**. I defined the University politics on the matter and chaired a committee composed of the representatives of all Departments.
2007 – 2017	**Member of University Committees**. I participated, representing my Department, in a number of Committees tha govern University activities: libraries (4 years), research (8 years), teaching evaluation (2 years), international affairs (4 years). In 2011, I was also a member of the 8-member Committee that re-wrote the University Statute and governance, owing to a radical change in legislation.

Representative contributions relating to the present application (drug regulation, pharmacoepidemiology and pharmacoutilization)

- Perini M, Castiglioni B, Galai E, Trapani D, Genazzani AA, Miglio G. (2025) Differences in the on-label cancer indications of medicinal products between Europe and the USA. ***Lancet Oncol***. 26:e103-e110. doi: 10.1016/S1470-2045(24)00434-0.
- Del Grosso V, Perini M, Casilli G, Costa E, Boscaro V, Miglio G, Genazzani AA. (2025) Performance of the accelerated assessment of the European Medicines Agency. ***Br J Clin Pharmacol***. 91:1439-1448. doi: 10.1111/bcp.16385.
- Costa E, Del Grosso V, Cappello B, Genazzani AA, Huttner B, Leufkens HGM, Magrini N, Nonino F, Wirtz VJ, van den Ham HA, Moja L. (2025) Medicines not recommended for inclusion in the who essential medicines list: a retrospective observational study. ***Front Med (Lausanne)***. 12:1517020. doi: 10.3389/fmed.2025.1517020.
- Casilli G, Lidonnici D, Jommi C, De Nigris M, Genazzani AA. (2023) Do France, Germany, and Italy agree on the added therapeutic value of medicines? ***Int J Technol Assess Health Care***. 39:e54. doi: 10.1017/S026646232300048X.
- Villa F, Di Filippo A, Pierantozzi A, Genazzani A, Addis A, Trifirò G, Cangini A, Tafuri G, Settesoldi D, Trotta F. (2022) Orphan Drug Prices and Epidemiology of Rare Diseases: A Cross-Sectional Study in Italy in the Years 2014-2019. ***Front Med (Lausanne)***. 9:820757. doi: 10.3389/fmed.2022.820757.
- Serafini M, Cargnin S, Massarotti A, Tron GC, Pirali T, Genazzani AA. (2021) What's in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications. ***J Med Chem***. 64:4410-4429. doi: 10.1021/acs.jmedchem.1c00181.
- Serafini M, Cargnin S, Massarotti A, Pirali T, Genazzani AA. (2020) Essential Medicinal Chemistry of Essential Medicines. ***J Med Chem***. 63:10170-10187. doi: 10.1021/acs.jmedchem.0c00415.
- Addis A, Genazzani A, Trotta MP, Magrini N; Italian Medicines Agency's Scientific Committee and COVID-19 Crisis Unit. (2020) Promoting Better Clinical Trials and Drug Information as Public Health Interventions for the COVID-19 Emergency in Italy. ***Ann Intern Med***. 173:654-655. doi: 10.7326/M20-3775.
- Belleudi V, Trotta F, Addis A, Ingrasciotta Y, Ientile V, Tari M, Gini R, Pastorello M, Scondotto S, Cananzi P, Traversa G, Davoli M, Trifirò G; (2019) Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study. ***Drug Saf***. 42:1437-1447. doi: 10.1007/s40264-019-00845-y.
- Da Cas R, Nigro A, Terrazzino S, Sances G, Viana M, Tassorelli C, Nappi G, Cargnin S, Pisterna A, Traversa G, Genazzani AA. (2015) Triptan use in Italy: Insights from administrative databases. ***Cephalalgia***. 35:619-26. doi: 10.1177/0333102414550419.

04/10/2025